Work

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.7051

Authors: Jorge E. Cortes, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Richard E Clark, Eric Leip, Andrea Viqueira, Vamsi Kota, Michael W.N. Deininger

Institutions: The University of Texas MD Anderson Cancer Center, Universitätsklinikum Aachen, RWTH Aachen University, University of Milano-Bicocca, Royal Liverpool University Hospital, Pfizer (United States), Pfizer (Spain), Augusta University, Augusta University Health, Oregon Health & Science University

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954494411

Cites:

Cited by: 1

Related to: 10